首页> 外文期刊>AJNR. American journal of neuroradiology >Local Anesthesia with Bupivacaine and Lidocaine for Vertebral Fracture trial (LABEL): a report of outcomes and comparison with the Investigational Vertebroplasty Efficacy and Safety Trial (INVEST).
【24h】

Local Anesthesia with Bupivacaine and Lidocaine for Vertebral Fracture trial (LABEL): a report of outcomes and comparison with the Investigational Vertebroplasty Efficacy and Safety Trial (INVEST).

机译:布比卡因和利多卡因用于椎体骨折的局部麻醉试验(LABEL):结果报告和与椎体成形术疗效和安全性试验(INVEST)的比较。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: INVEST is a recently published double-blind placebo controlled randomized trial that demonstrated similar improvements in pain between blinded vertebroplasty and sham-vertebroplasty groups. LABEL is a trial determining the efficacy of pain relief of an injection of lidocaine and bupivacaine at the site of painful osteoporotic vertebral compression fractures in unblinded patients. We compared outcomes from the unblinded LABEL trial with those of blinded control patients from the lead site of the INVEST, exploring the role of blinding on the benefit of local anesthesia infusion for painful vertebral compression fractures. MATERIALS AND METHODS: Nineteen patients with painful osteoporotic vertebral compression fractures underwent unblinded injection of lidocaine and bupivacaine at the site of painful osteoporotic vertebral compression fractures. Patients were given the option of undergoing vertebroplasty at any time following the procedure. Primary outcome measures were change in the RDQ and pain (at rest, with activity, and average 24-hour pain) at days 1 and 3 following the injection. Day 3 change in RDQ scores and change in average 24-hour pain were compared for LABEL and INVEST control patients from the lead site (n = 16). RESULTS: Among patients in the LABEL trial, we detected no significant improvement in RDQ scores, pain at rest, and average 24-hour pain at days 1 and 3, whereas pain with activity improved significantly at both time points. INVEST control patients from the lead site experienced significantly greater improvement in average pain during 24 hours at days 1 (P = .03) and 3 (P = .04) and significantly greater improvements in RDQ scores at day 3 (P = .006) than patients from LABEL. CONCLUSIONS: An unblinded injection of local anesthesia is ineffective in treating pain from osteoporotic compression fractures. This suggests that factors other than local anesthesia were responsible for the observed improvement in the control group in INVEST.
机译:背景与目的:INVEST是最近发表的一项双盲安慰剂对照随机试验,该试验显示了盲椎椎体成形术和假椎体成形术组之间疼痛的相似改善。 LABEL是一项试验,用于确定在无盲患者的疼痛性骨质疏松性椎体压缩性骨折部位注射利多卡因和布比卡因的镇痛效果。我们将无盲LABEL试验的结果与INVEST领先部位的盲对照患者的结果进行了比较,探讨了盲法对疼痛性椎体压缩性骨折局部麻醉输注的益处。材料与方法:19例痛苦的骨质疏松性椎体压缩性骨折患者,在痛苦的骨质疏松性椎体压缩性骨折部位接受了利多卡因和布比卡因的无盲注射。在手术后的任何时间,患者都可以进行椎体成形术。主要结果指标是注射后第1天和第3天的RDQ和疼痛(静止,活动,平均24小时疼痛)的变化。比较了主要部位的LABEL和INVEST对照患者的RDQ评分第3天变化和平均24小时疼痛变化(n = 16)。结果:在LABEL试验的患者中,我们没有发现RDQ评分,休息时疼痛以及第1天和第3天的平均24小时疼痛都没有明显改善,而活动时的疼痛在这两个时间点上都有明显改善。来自铅部位的INVEST对照患者在第1天(P = .03)和第3天(P = .04)的24小时内平均疼痛明显改善,在第3天RDQ得分明显改善(P = .006)比来自LABEL的患者要多。结论:无盲法局部麻醉注射不能有效治疗骨质疏松性压缩性骨折引起的疼痛。这表明,在INVEST的对照组中,观察到的局部改善是局部麻醉以外的因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号